Clinical development of targeted and immune based anti-cancer therapies | Journal of Experimental & Clinical Cancer Research | Full Text
Bevacizumab for malignant gliomas: current indications, mechanisms of action and resistance, and markers of response | SpringerLink
Role of bevacizumab in colorectal cancer growth and its adverse effects: A review
Mechanism of action of Bevacizumab (Avastin), binding VEGF and avoiding... | Download Scientific Diagram
Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook - Cancer Treatment Reviews
Bevacizumab | Nature Reviews Drug Discovery
Bevacizumab-bvzr (Zirabev) Drug Information
A functional bioassay to determine the activity of anti-VEGF antibody therapy in blood of patients with cancer | British Journal of Cancer
Angiogenesis inhibitor - Wikipedia
References in Nephrotoxicity induced by intravitreal vascular endothelial growth factor inhibitors: emerging evidence - Kidney International
Bevacizumab and breast cancer: what does the future hold? | Future Oncology
Mechanism of action of Bevacizumab (Avastin), binding VEGF and avoiding... | Download Scientific Diagram
Avastin® (bevacizumab) For HCP's | NSCLC Treatment
AVASTIN® (bevacizumab) - Cancer Therapy Advisor
ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Cell surface receptors and associated signaling pathways) - Clinical
Avastin (bevacizumab) - Angiogenesis Inhibitor and Cancer Therapy - Clinical Trials Arena
Development of bevacizumab in advanced cervical cancer: pharmacodynamic modeling, survival impact and toxicology. - Abstract - Europe PMC
Scheme 1. The mechanism of action of bevacizumab. (Modified from:... | Download Scientific Diagram
Association of ranibizumab (Lucentis®) or bevacizumab (Avastin®) with dexamethasone and triamcinolone acetonide: An in vitro stability assessment - ScienceDirect
Antiangiogenic Agents and the Skin: Cutaneous Adverse Effects of Sorafenib, Sunitinib, and Bevacizumab - ScienceDirect
Bevacizumab-awwb becomes first biosimilar approved for cancer treatment | MDedge Hematology and Oncology
New Ways to Inhibit the VEGF Pathway in Metastatic Colorectal Cancer
Mechanisms of Action of Bevacizumab as a Component of Therapy for Metastatic Colorectal Cancer - ScienceDirect
Existing anti-angiogenic therapeutic strategies for patients with metastatic colorectal cancer progressing following first-line bevacizumab-based therapy
Atezolizumab and bevacizumab for hepatocellular carcinoma: mechanism, pharmacokinetics and future treatment strategies | Future Oncology
Avastin® (bevacizumab) Proposed MOA | MCRC Treatment
